StockWatch
·

CAPLIN POINT LABORATORIES LTD. Q2 FY27 Results

CAPLIPOINTQ2 FY27 Results
Filing
Result:Good· Market: Crashed#Margin squeeze#Record quarter
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue629.843.2%17.9%
Total Income663.133.0%17.5%
Expenditure430.332.8%18.4%
PBT232.833.4%15.8%
Net Profit182.351.8%13.8%
OPM35.45%0.47pp0.03pp
NPM27.50%0.31pp0.89pp
EPS23.440.7%15.3%
View full financials

Revenue grew a healthy 17.9% YoY to a 6-quarter high and PAT rose 13.8% to a 6-quarter high with no one-offs, but PBT/PAT margins compressed YoY as US-segment profitability fell sharply, so core profitability quality was below the growth headline — good, not very_good.

Q2 FY-2027 RESULTS · CAPLIPOINT

Caplin Point Q2FY27: consolidated PAT ₹182 Cr, +13.8% YoY, as US segment profit dips QoQ

PAT +13.81% YoY · revenue +17.94% · margins compressing

12 Nov 2026 · 3 min read
Revenue

₹629.84 Cr

+17.94% YoY

PAT (consolidated)

₹182.35 Cr

+13.81% YoY

Net margin

27.5%

-0.9pp YoY

EPS

₹23.44

Caplin Point's consolidated (primary) revenue rose 17.9% YoY to ₹629.84 Cr and PAT grew 13.8% YoY to ₹182.35 Cr (₹178.10 Cr attributable to owners, EPS ₹23.44) for Q2FY27, with no exceptional items on either side of the comparison. QoQ growth was modest — revenue +3.2%, PAT +1.8% over Q1FY27's ₹610.36 Cr/₹179.09 Cr — consistent with the company's steady, non-seasonal growth pattern rather than any acceleration or slowdown signal. Standalone PAT was ₹130.51 Cr on revenue of ₹241.88 Cr, secondary to the consolidated print.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹629.84 Cr+3.2%+17.9%
Expenses₹430.33 Cr+2.8%+18.4%
PAT₹182.35 Cr+1.82%+13.81%
Net margin27.5%-0.3pp-0.9pp
EPS₹23.44+0.7%+15.4%

Margins were mixed and the net effect was mild compression: gross margin expanded to 62.1% from 60.6% a year ago and 59.8% last quarter, but EBITDA margin eased to 38.7% from 38.9% YoY, PBT margin to 35.1% from 35.6%, and PAT margin to 27.5% from 28.4% — meaning opex (employee costs and other expenses) grew faster than gross profit. The driver sits in the US segment: segment PBT fell to ₹16.32 Cr from ₹33.27 Cr in Q1FY27 (-51% QoQ) even though US segment revenue was roughly flat (₹129.72 Cr vs ₹134.29 Cr), while the Rest-of-World (Latin America/Africa) segment carried the quarter with PBT up to ₹183.22 Cr from ₹156.10 Cr a year ago (+17.4% YoY) on revenue of ₹500.12 Cr (+17.1% YoY).

₹
2,144.12,344.32,544.52,744.72,944.92,495.208-1009-0109-2410-1911-1111-12Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹2,495.2, up 5.7% over the past month of trading.

₹ Cr
068.08136.15204.23150.76Q1 FY26rev ₹510 Cr160.23Q2 FY26rev ₹534 Cr165.86Q3 FY26rev ₹543 Cr172.88Q4 FY26rev ₹600 Cr179.09Q1 FY27rev ₹610 Cr182.35Q2 FY27rev ₹630 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.

Beyond the headline

What the summary numbers don't show

Free cash reserves ₹1,534 Cr, total liquid assets ₹2,967 Cr — ~₹1,000+ Cr capex programme (incl. COL-II injectable facility due Aug 2027) to be funded entirely from internal accruals, company to stay net-cash positive

There is no formal management guidance on record for this quarter, and no quarter-specific Street consensus for Q2FY27 PAT/revenue could be located, so both vs-guidance and vs-Street comparisons are unknown; the only external data point found was a full-year FY27 consensus revenue estimate of roughly ₹2,490 Cr (+13.8% YoY), broadly consistent with the H1FY27 run-rate of ₹1,307 Cr. The quarter's own-label US business, Caplin Steriles USA (CSU), already surpassed its full FY26 sales within H1FY27, with average daily sales nearly doubling to $61,330 from $32,936 in FY26 and unique customers up 20% over FY26 — a front-end scaling story that sits alongside the segment PBT dip, suggesting near-term reinvestment/ramp costs rather than demand weakness. Management also flagged new tenders won in Central America ($5.3 million) and Chile ($5 million), the start of oncology sales in Mexico, and an enhanced ~₹1,000+ Cr capex programme (COL-II injectable facility targeted for Aug 2027) to be funded entirely from internal accruals. Chairman Dr. C.C. Paarthipan characterised H1FY27 as "another half of disciplined, broad-based growth" with margins having "held firm" — a framing the quarterly print only partly supports, since consolidated margins are down YoY even as EBITDA grew 16.8% YoY in absolute terms.

  • W1

    USA segment PBT recovery — fell to ₹16.32 Cr in Q2FY27 from ₹33.27 Cr in Q1FY27 on near-flat revenue; watch for rebound in Q3FY27

  • W2

    CSU's stated goal to double revenue and profit over FY27 (daily sales already $61,330 vs $32,936 in FY26) — track H2FY27 trajectory

  • W3

    COL-II injectable/ophthalmic facility (Gummidipoondi) targeted for completion by Aug 2027, central to the ~₹1,000+ Cr capex plan — watch for commissioning progress

No exceptional items in current or year-ago quarter; consolidated net profit of ₹182.35 Cr includes ₹4.25 Cr non-controlling interest (owners' share ₹178.10 Cr, basic EPS ₹23.44); standalone other income includes ₹15.19 Cr dividend from wholly-owned subsidiary Caplin Point Far East.

Informational and educational content only. Not investment advice.